Thursday, 13 Dec 2018

You are here

SPAR Predicts ILD Progression in Systemic Sclerosis

The development and progression of interstitial lung disease in systemic sclerosis can be an ominous finding. A new analysis of two independent clinical trial cohorts shows that oxygen saturation (SpO2) < 94% after 6 minute walk time (6MWT) and the presence of arthritis predicted the development of ILD in SSc. (SPAR: SPO2 and ARthritis) 

A total of 215 SSc patients with mild ILD (without pulmonary HTN or COPD) were followed prospectively with SpO2 levels, high-resolution computed tomography (HRCT) and pulmonary function tests.

ILD progression was defined as a relative decrease in forced vital capacity (FVC) ≥15%, or FVC ≥10% combined with diffusing capacity for carbon monoxide (DLCO) ≥15% at 1-year.

Between 21-26% of SSc patients showed ILD progression. Independent predictors of progression included lower SpO2 after 6MWT and arthritis.

This SPAR model (SPO2 and ARthritis) increased the prediction rate from 25.5% to 91.7% with an area under the curve of 0.83 (95% CI: 0.73 to 0.93).

These simple measures might be helpful for the risk stratification of SSc patients. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Genetic Diagnosis for Previously Undiagnosed Disorders

The NEJM has reported the NIH's Undiagnosed Diseases Network (UDN) study results of genetically identifying new diseases from prospectively followed persons with undiagnosed disorders. The UDN was formed in 2014 as a network of seven clinical sites, two sequencing cores, a coordinating center, central biorepository, a metabolomics core, and a model organisms screening center. It was established to apply a multidisciplinary model in the evaluation of the most challenging cases and to identify the biologic characteristics of newly discovered diseases.

SLE and Risk of Malignancy

The risk for cancer in systemic lupus erythematosus (SLE) patients has been inconsistently studied.  A new metanalysis shows that SLE has an increased risk for 16 specific cancers and decreased risk for prostate cancer and cutaneous melanoma. 

The Benefits of a Lupus Clinic

A comparative cohort study assessing the quality of care in patients with systemic lupus erythematosus (SLE) suggests that a dedicated lupus clinic has better quality measure performance compared to lupus management in a general rheumatology clinic.

A study from Rush University enrolled 150 consecutive SLE patients - with 73 followed in the general rheumatology clinic and 77 followed in a dedicated lupus clinic. 

Diagnosing Early Lupus from Mimics

A multicenter study of early systemic lupus erythematosus (SLE) patients examined manifestations at disease onset and found that certain clinical features can help to distinguish early SLE from other SLE‐mimicking conditions. 

High CV Risk in Lupus

Patients with systemic lupus erythematosus (SLE) remain at risk for accelerated atherosclerosis, and important questions have yet to be answered, British investigators reported.